Cargando…

Exanthematous Drug Eruption to Intravenous Iron: A Case Report

The authors present a rare case of an exanthematous drug reaction to intravenous iron. Exanthematous drug eruptions, also called morbilliform or maculopapular drug rashes, can occur in first-time drug exposures and represent a subtype of delayed-type IV hypersensitivity reactions.  This patient is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantri, Shilpa S, Ballam Nagaraj, Niraj, Patel, Chirag, Solanki, Kinjal, Rana, Haris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915382/
https://www.ncbi.nlm.nih.gov/pubmed/35340473
http://dx.doi.org/10.7759/cureus.22045
_version_ 1784668009547169792
author Mantri, Shilpa S
Ballam Nagaraj, Niraj
Patel, Chirag
Solanki, Kinjal
Rana, Haris
author_facet Mantri, Shilpa S
Ballam Nagaraj, Niraj
Patel, Chirag
Solanki, Kinjal
Rana, Haris
author_sort Mantri, Shilpa S
collection PubMed
description The authors present a rare case of an exanthematous drug reaction to intravenous iron. Exanthematous drug eruptions, also called morbilliform or maculopapular drug rashes, can occur in first-time drug exposures and represent a subtype of delayed-type IV hypersensitivity reactions.  This patient is a 49-year-old female with a history of iron deficiency anemia and hypothyroidism who presented to the emergency department after experiencing a diffuse whole-body maculopapular rash following ferumoxytol 510 mg intravenously received once two days prior to her presentation. A clinical examination was suspicious of an exanthematous drug eruption. The patient was treated with methylprednisolone 40 mg intravenously twice a day for three days, followed by prednisone 40 mg orally twice a day for two days with a steroid taper upon discharge. The patient’s rash resolved within five days of steroid treatment. There is a high global prevalence of iron deficiency anemia for which intravenous iron replacement may be required. However, there is limited research addressing its adverse effects, particularly those that include delayed hypersensitivity reactions. This paper aims to alert healthcare professionals of a rare type of delayed hypersensitivity reaction to intravenous iron to better guide management in the clinical setting. 
format Online
Article
Text
id pubmed-8915382
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-89153822022-03-25 Exanthematous Drug Eruption to Intravenous Iron: A Case Report Mantri, Shilpa S Ballam Nagaraj, Niraj Patel, Chirag Solanki, Kinjal Rana, Haris Cureus Internal Medicine The authors present a rare case of an exanthematous drug reaction to intravenous iron. Exanthematous drug eruptions, also called morbilliform or maculopapular drug rashes, can occur in first-time drug exposures and represent a subtype of delayed-type IV hypersensitivity reactions.  This patient is a 49-year-old female with a history of iron deficiency anemia and hypothyroidism who presented to the emergency department after experiencing a diffuse whole-body maculopapular rash following ferumoxytol 510 mg intravenously received once two days prior to her presentation. A clinical examination was suspicious of an exanthematous drug eruption. The patient was treated with methylprednisolone 40 mg intravenously twice a day for three days, followed by prednisone 40 mg orally twice a day for two days with a steroid taper upon discharge. The patient’s rash resolved within five days of steroid treatment. There is a high global prevalence of iron deficiency anemia for which intravenous iron replacement may be required. However, there is limited research addressing its adverse effects, particularly those that include delayed hypersensitivity reactions. This paper aims to alert healthcare professionals of a rare type of delayed hypersensitivity reaction to intravenous iron to better guide management in the clinical setting.  Cureus 2022-02-09 /pmc/articles/PMC8915382/ /pubmed/35340473 http://dx.doi.org/10.7759/cureus.22045 Text en Copyright © 2022, Mantri et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Mantri, Shilpa S
Ballam Nagaraj, Niraj
Patel, Chirag
Solanki, Kinjal
Rana, Haris
Exanthematous Drug Eruption to Intravenous Iron: A Case Report
title Exanthematous Drug Eruption to Intravenous Iron: A Case Report
title_full Exanthematous Drug Eruption to Intravenous Iron: A Case Report
title_fullStr Exanthematous Drug Eruption to Intravenous Iron: A Case Report
title_full_unstemmed Exanthematous Drug Eruption to Intravenous Iron: A Case Report
title_short Exanthematous Drug Eruption to Intravenous Iron: A Case Report
title_sort exanthematous drug eruption to intravenous iron: a case report
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915382/
https://www.ncbi.nlm.nih.gov/pubmed/35340473
http://dx.doi.org/10.7759/cureus.22045
work_keys_str_mv AT mantrishilpas exanthematousdrugeruptiontointravenousironacasereport
AT ballamnagarajniraj exanthematousdrugeruptiontointravenousironacasereport
AT patelchirag exanthematousdrugeruptiontointravenousironacasereport
AT solankikinjal exanthematousdrugeruptiontointravenousironacasereport
AT ranaharis exanthematousdrugeruptiontointravenousironacasereport